ResMed has beaten earnings forecasts in the second quarter due to higher sales of its sleep device products and masks despite fears that the take-up of weight-loss drugs would reduce demand as people breathe easier at night.
ResMed’s revenue rose 10 per cent to $US1.3 billion, profit margins expanded, and net income jumped 65 per cent to $US344.6 million ($555 million) for the three months ended December 31.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.